Prevalence and Risk Factors for Venous Thromboembolic Events in Critically Ill Patients With COVID-19
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04567927 |
Recruitment Status :
Completed
First Posted : September 29, 2020
Last Update Posted : September 29, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
SARS Virus | Other: Ultrasonography |
Study Type : | Observational |
Actual Enrollment : | 80 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Prevalence and Risk Factors for Venous Thromboembolic Events in Critically Ill Patients With SARS-CoV-2 Infection |
Actual Study Start Date : | March 3, 2020 |
Actual Primary Completion Date : | May 28, 2020 |
Actual Study Completion Date : | May 28, 2020 |
- Other: Ultrasonography
Venous compression ultrasonography using real-time B-mode and colour doppler in transverse and longitudinal views
- Period prevalence of deep vein thrombosis (DVT) [ Time Frame: From date of inclusion in the study until the date of development of a DVT, date of death from any cause, or date of discharge from the ICU, whichever came first, assessed up to 3 months ]Percent (%) of patients with a DVT

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- patients admitted to the Intensive Care Unit
- laboratory confirmed SARS-CoV-2 infection
- invasive respiratory support
Exclusion Criteria:
- none

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04567927
Switzerland | |
Ospedale Regionale di Bellinzona e Valli | |
Bellinzona, Ticino, Switzerland, 6500 |
Responsible Party: | Chiesa Alessandro Felice, Principal Investigator, Ente Ospedaliero Cantonale, Bellinzona |
ClinicalTrials.gov Identifier: | NCT04567927 |
Other Study ID Numbers: |
2020-01266 |
First Posted: | September 29, 2020 Key Record Dates |
Last Update Posted: | September 29, 2020 |
Last Verified: | September 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Thromboembolism Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases |